Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Phase 1 trial demonstrates safety of arlocabtagene autoleucel combined with mezigdomide in relapsed multiple myeloma, suggesting improved treatment options.
Key Points
The study aims to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel and mezigdomide in patients with relapsed/refractory multiple myeloma.
Phase 1, open-label, multicenter trial conducted in the US and Canada.
Patients receive arlocabtagene autoleucel followed by mezigdomide after lymphodepleting chemotherapy.
Dose-limiting toxicities are monitored for treatment safety.
The trial focuses on determining the recommended phase 2 dose based on dose-limiting toxicities.
Primary endpoints include safety assessments of adverse events and establishing the recommended phase 2 dose.